{"prompt": "['Product: MK-3475', '51', 'Protocol/Amendment No.: 604-09', 'For patients receiving cisplatin, the scheduled dose of cisplatin may only be administered if', 'the calculated CrCl is >50 mL/min:', 'If CrCl falls to <50 mL/min, delay the start of that cycle for 21 days. In the interim,', 'monitor renal function weekly and consider intravenous (IV) hydration. When CrCl', 'improves to >50 mL/min, decrease cisplatin to dose level (DL) -1 (Table 3).', \"Alternatively, if in the investigator's judgment it is in the best interest of the patient,\", 'cisplatin can be switched to carboplatin if the calculated CrCl is appropriate, and in', 'consultation with the Sponsor.', 'At the second occurrence of CrCl <50 mL/min, decrease cisplatin to DL -2 upon', \"improvement of CrCl to >50 mL/min. Alternatively, if in the investigator's judgment\", 'it is in the best interest of the patient, cisplatin can be switched to carboplatin if the', 'calculated CrCl is appropriate, and in consultation with the Sponsor.', 'At the third occurrence of CrCl <50 mL/min, cisplatin should be discontinued. If in', \"the investigator's judgment it is in the best interest of the patient, cisplatin can be\", 'switched to carboplatin if the calculated CrCl is appropriate, at the discretion of the', 'investigator and in consultation with the Sponsor.', 'For patients receiving carboplatin, the scheduled dose of carboplatin may only be', 'administered if the calculated CrCl is >40 mL/min:', 'If CrCl falls to <40 mL/min, delay the start of that cycle for <21 days. In the interim,', 'monitor renal function weekly and consider IV hydration. When CrCl improves to', '>40 mL/min, decrease carboplatin to DL - 1 (Table 3).', 'At the second occurrence of CrCl <40 mL/min, decrease carboplatin to DL -2 upon', 'improvement of CrCl to >40 mL/min.', 'At the third occurrence of CrCl <40 mL/min, carboplatin should be discontinued.', '5.2.2 Timing of Dose Administration', 'All trial treatments will be administered on an outpatient basis.', 'Trial treatment should be administered beginning on Day 1 of each cycle after all procedures', 'and assessments have been completed (time points listed in Section 6). Day 1 of each cycle', 'should occur as scheduled (or in a window of 3 days for administrative reasons only).', 'Etoposide must be administered on 3 consecutive days without interruption (Days 1, 2,', 'and 3) in Cycles 1 to 4.', 'For subjects who experience disease progression, investigators may elect to continue trial', 'treatment until confirmation of disease progression or may elect to interrupt treatment by', 'deferring the decision to continue/discontinue treatment in the trial until confirmation of', 'disease progression per modified RECIST 1.1 at least 28 days from the date of imaging', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '52', 'Protocol/Amendment No.: 604-09', 'demonstrating disease progression. Subjects for whom disease progression is not confirmed', 'on subsequent imaging may resume treatment. Please see Section 5.8 for other exceptions.', '5.2.2.1 Pembrolizumab (or Saline Placebo)', 'Pembrolizumab or saline placebo will be administered first in the sequence of medications.', 'Upon completion of the pembrolizumab or saline placebo infusion, premedication for the', 'chemotherapy should be administered as per local SOC, followed by chemotherapy.', 'Pembrolizumab or saline placebo will be administered as a 30-minute IV infusion Q3W on', 'Day 1 of each cycle. Sites should make every effort to target infusion timing to be as close to', '30 minutes as possible. However, given the variability of infusion pumps from site to site, a', 'window of -5 minutes to +10 minutes is permitted (ie, infusion time is 25 to 40 minutes).', 'The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation,', 'reconstitution, infusion fluid preparation, and administration.', '5.2.2.2 Chemotherapy', 'Chemotherapy should be administered as described in the following subsections. Subjects are', 'allowed to switch from cisplatin to carboplatin, if the subject becomes ineligible for further', 'cisplatin therapy according to local guidelines and the investigator considers switching to', 'carboplatin to be in the best interest of the subject.', '5.2.2.2.1 Carboplatin', 'Carboplatin at a dose calculated to achieve an area under the plasma drug concentration time', 'curve (AUC) of 5 will be administered as an IV infusion over approximately 60 minutes', 'Q3W on Day 1 for 4 cycles. Carboplatin dose should not exceed 750 mg. AUC should be', 'calculated using the Calvert formula:', 'Total dose (mg) = (target AUC) X (CrCl + 25)', 'The estimated CrCl in the Calvert formula should not exceed 125 mL/min', 'Maximum carboplatin dose (mg) = target AUC 5 X (125+25)', '= 5 X 150', '= 750 mg', 'Creatinine clearance must be calculated using either the Cockcroft-Gault formula or another', 'acceptable standard formula for estimating CrCl in mL/min based on serum creatinine:', 'Men: [(140-age(())) X weight (kg)]/[72 X serum creatinine (mg/dL)', 'Women: [(140-age((y)) X weight (kg)] X 0.85/[72 X serum creatinine (mg/dL)]', 'Note: Due to differences in serum creatinine units, sites may use either the standard', 'Cockcroft-Gault formula or another acceptable standard formula used at their institution.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}